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Abstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop 
a complex of body composition changes known, including peripheral fat loss (lipoatrophy) 
and central fat accumulation (lipohypertrophy). These changes may cause significant patient 
distress, which could in turn interfere with adherence to antiretroviral therapy. Treatment 
options – including antiretroviral switch, insulin sensitizers, and surgical approaches – have 
been associated with limited success and potential complications. The observation that low 
growth hormone levels are associated with central fat accumulation among HIV patients has 
led to the development of tesamorelin (a growth hormone releasing hormone analog) for 
the management of central fat accumulation. Randomized controlled trials have shown that 
administration of tesamorelin is safe and effective in reducing central fat accumulation among 
HIV-infected patients. This effect is transient, however, and its association with improved 
cardiovascular risk remains unclear.
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Introduction
The introduction and widespread use of protease inhibitors (PI) in the context of highly 
active antiretroviral therapy (HAART) in the mid-1990s has been associated with a 
dramatic reduction in the mortality of HIV-infected patients.1–8 However, new adverse 
events associated with various antiretroviral regimens were soon recognized, and 
were collectively referred to as the lipodystrophy syndrome.9–11 When first introduced, 
the term HIV-associated lipodystrophy referred to alterations in the distribution of 
body fat and impaired glucose or lipid metabolism, and shared similar features with 
other less prevalent acquired and inherited forms of lipodystrophy12 and metabolic 
syndrome.13,14
For reasons that include a lack of standard objective diagnostic criteria and 
  differences in study designs and study populations, determining the true prevalence of 
lipodystrophy in HIV-infected patients receiving antiretroviral therapy was difficult, 
with estimates varying in some reports from 8% to 84%.15 It has also been demonstrated 
that in many patients receiving antiretroviral therapy, central fat accumulation (lipo-
hypertrophy) is distinct etiologically and pathologically from peripheral fat changes 
manifesting as lipoatrophy.16,17 The former has been mostly associated with long-term 
exposure to PIs and the latter to nucleoside reverse transcriptase inhibitors (NRTIs).
The body composition changes associated with lipodystrophy may cause significant 
patient distress that could in turn interfere with adherence to antiretroviral therapy.18 
Also, waist circumference and visceral adipose tissue (VAT) have been shown to be HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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independent predictors of cardiovascular morbidity and 
mortality.19 This has led some to suggest that management 
of lipodystrophy could improve HIV patients’ cardiovascular 
morbidity.
The heterogeneity of body fat abnormalities among HIV-
infected patients, as well as the incompletely understood 
pathophysiologic mechanisms and the role of antiretroviral 
therapy, make management decisions difficult to devise. 
Therapeutic options are therefore limited.20 Antiretroviral 
treatment interruption has been associated with adverse 
outcomes, including worsening of the cardiovascular 
risk.21 Insulin sensitizers have been tried with limited 
success.22,23 Surgery – either excision or liposuction24 – or 
nonsurgical cosmetic approaches25,26 have also had limited 
and transient success.
HIV-infected patients with lipodystrophy have been found 
to have low levels of growth hormone (GH).27 Increasing 
endogenous GH may reduce triglycerides (TG) and overall 
cholesterol levels through inhibition of de novo lipogenesis 
and increase in fat oxidation. This has led to investigation of 
the manipulation of the GH axis in the management of central 
fat accumulation, leading to the discovery of tesamorelin 
(a growth hormone releasing factor). The current review 
focuses on the pathophysiological basis and the clinical 
evidence for the use of tesamorelin in the management of 
abdominal fat accumulation among HIV-infected patients.
HIV-associated lipodystrophy
Changes in the distribution of body fat are generally 
referred to as “lipodystrophy”, “fat maldistribution”, “fat 
redistribution”, or “body habitus changes”. Lipodystrophy 
is typically identified in the clinic by physical examination 
and patient self-report. A variety of techniques are used to 
measure body fat, including anthropometry, bioimpedance 
analysis (BI), dual-energy X-ray absorptiometry (DEXA), 
computed tomography (CT), magnetic resonance imaging 
(MRI), and ultrasonography. Each technique has limitations, 
however.28 Despite the proposal of a case definition for the 
diagnosis of HIV-associated lipodystrophy in 2003, it has 
not been widely adopted because it requires the use of CT 
and DEXA scans.29–31
HIV-infected individuals may exhibit different patterns 
and varying degrees of severity of changes in body fat. 
Two distinct types of body-fat changes are lipoatrophy (fat 
loss) and lipohypertrophy (fat accumulation). Lipoatrophy 
is characterized by subcutaneous fat depletion in the face, 
arms, legs, and buttocks. The preservation of lean body 
mass (primarily muscle) in lipoatrophy distinguishes this 
condition from HIV wasting syndrome, which is defined as 
the generalized loss of body fat and lean body mass with an 
involuntary weight loss of more than 10% of baseline body 
weight.15,29
Lipoatrophy and lipohypertrophy may manifest 
  separately or together (ie, mixed form) in an individual,17,32–35 
which   suggests that peripheral lipoatrophy and central 
lipohypertrophy are not linked phenomena, but separate 
entities that develop independently.29
Management of HIV-associated 
lipodystrophy
At this time, no guidelines exist for the management of the 
body shape changes associated with HIV infection and/or 
antiretroviral therapy. However, a set of recommendations 
for managing body-fat changes have been published, only one 
of which is evidence-based.30,36,37 These recommendations 
examine several approaches: antiretroviral substitution, 
  lifestyle modification (eg, diet and exercise), cosmetic 
  interventions, and pharmacologic interventions. The   latter 
have been hampered by the incompletely understood 
pathophysiologic mechanisms (discussed in the next section). 
Given the heterogeneity of the lipodystrophy syndrome, it is 
unsurprising that different therapeutic interventions have had 
various outcomes on visceral adipose tissue and peripheral 
adipose tissue.
Antiretroviral therapy modification
Clinical trials and observational studies have reported variable 
results on changes in abdominal fat following antiretroviral 
therapy switch. While a small study showed improvement in 
VAT and insulin resistance upon switching from a lopinavir/
ritonavir-containing to an atazanavir-containing regimen,38 
these findings were not confirmed in a larger study of switch 
to atazanavir from other boosted PI.39 Replacement of a pro-
tease inhibitor with abacavir, nevirapine, or efavirenz also did 
not significantly change abdominal obesity.40,41 Finally, most 
studies did not show a significant improvement in visceral 
adipose tissue following a switch from thymidine-analog 
nucleoside reverse transcriptase inhibitor to a nonthymidine 
analog regimen, or to a nucleoside-sparing regimen.42–44
Surgery and nonsurgical cosmetic 
approaches
Surgery, either excision or liposuction, has been performed 
on patients with body-fat changes and may be useful in 
removing dorsocervical fat pads, although there may be a risk 
of recurrence.24 Nonsurgical cosmetic approaches include HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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dermal fillers injected under the skin to restore and correct 
the signs of facial fat loss.25,26 Two products, poly-L-lactic 
acid (SculptraTM, sanofi-aventis) and calcium hydroxylapatite 
(Radiesse®, Merz Aesthetics, Inc), are FDA approved for the 
correction of lipoatrophy in persons with HIV .45 Although 
both have been reported to improve facial lipoatrophy with 
few adverse events, findings from a small randomized, mul-
ticenter trial evaluating poly-L-lactic acid treatment using 
CT revealed that such treatment did not increase facial soft 
tissue volume overall.47 Nevertheless, patients and clinicians 
report that physical appearance is noticeably improved with 
these products.
Physical activity and diet are recommended for the 
  management of metabolic abnormalities in the general 
  population and have been shown to have modest, but 
  significant reductions in waist circumference (visceral 
  adipose tissue) among HIV-infected patients.48–50
Nonantiretroviral pharmacologic 
interventions
A number of agents are being investigated as potential 
pharmacological interventions to manage fat accumulation. 
The insulin sensitizers, metformin and rosiglitazone, have 
been reported to have conflicting effects on improving 
fat accumulation. Metformin may decrease visceral fat, 
but also subcutaneous abdominal fat, and peripheral fat.22 
Rosiglitazone does not appear to improve body fat changes,23 
but recent evidence suggests that it might do so among 
patients using thymidine-sparing regimens.51 In men with 
central fat accumulation, testosterone therapy significantly 
decreased total body, trunk, and limb subcutaneous fat, but 
did not change visceral fat.52
In at least some patients, the weight gain observed 
following antiretroviral therapy initiation might signify a 
return to “health” with the attendant metabolic syndrome that 
is very prevalent in the non-HIV population. However, it is 
likely that the lack of improvement in central fat accumulation 
that is observed in most of the studies mentioned above stems 
from an incomplete understanding of the pathophysiologic 
mechanisms underlying the changes and how to safely and 
effectively interfere with them.
Pathophysiology of body-fat changes
Lipodystrophy is considered to be multifactorial, resulting 
from the complex interaction of host factors, disease factors, 
and antiretroviral drug treatment.29 As mentioned above, 
evidence suggests that lipoatrophy and lipohypertrophy 
are two separate syndromes,17,32–35 the former being mostly 
associated with long-term exposure to PIs and the latter 
to NRTIs. Therefore, it is unlikely that there is a single 
pathophysiologic process responsible for the observed fat 
accumulation and loss. Several working hypotheses have 
been proposed to explain the development of body-fat 
changes.53–55 Some of the proposed pathogenic mechanisms 
are mediated by HIV infection itself and the host response 
to the infection (which could be potentiated by antiretroviral 
exposure), and others are linked to specific antiretroviral 
drugs or drug classes.
Virus–host interactions  
and the pathogenesis of lipodystrophy
A number of research groups have posited that immune 
dysregulation caused by HIV plays a role in fat redistribution. 
According to one model, the initial steps in the pathogenesis 
of body-fat changes are triggered by HIV infection and the 
development of a persistent inflammatory state, which is 
mediated by proinflammatory cytokines and the action of 
viral proteins with paracrine and endocrine actions on adipose 
tissue that alters adipocyte differentiation and function.54
Adipocyte dysfunction appears to play a key role in the 
development of body-fat changes, and several mechanisms 
have been identified that impair adipocyte differentiation 
and apoptosis.29,53–55 However, adipose tissue has a complex 
structure (populated by several different cell types) 
and function (regulation of fat metabolism and its own 
glucocorticoid metabolism).56 Adding to this complexity, 
adipose tissue receives hormonal and neuronal signals, and the 
subcutaneous and visceral compartments differ functionally, 
metabolically, and genetically.53,54,56 The disruption of 
specific pathways may be responsible for specific features 
and/or the severity of body habitus changes.
HIV infection may induce body fat changes by 
virtue of structural homology between viral and cellular 
proteases and/or downregulation of nuclear genes encoding 
mitochondrial proteins.54 This might be further compounded 
by antiretroviral therapy.
Several other mechanisms involved in the pathogenesis of 
body-fat changes have been reported, including alterations in 
cytokines, adipokines, leptin, and adiponectin. Significantly 
increased levels of the pro-inflammatory cytokine tumor 
necrosis factor alpha (TNFα) have been found in HIV 
patients with body-fat changes,57,58 and significantly 
increased mRNA expression of TNFα in subcutaneous 
adipose fat.59 TNF-α inhibits adipocyte differentiation and 
insulin sensitivity, but increases lipolysis, apoptosis, and 
mitochondrial toxicity.55HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Finally, data are beginning to provide insight into 
the involvement of the hormonal-adipocyte axis in HIV-
associated body-fat changes. Leptin and adiponectin are 
adipocyte hormones that play key roles in the regulation 
of energy homeostasis and insulin resistance.60 Changes 
in leptin61 and adiponectin62 levels have been observed in 
HIV-infected patients with lipodystrophy. The importance 
of the hypothalamic-pituitary axis in the pathogenesis of 
lipodystrophy is discussed separately in the next section.
Pathogenic mechanisms of lipodystrophy induced 
by   different antiretroviral drug classes NRTIs induce 
mitochondrial toxicity. Ultrastuctural abnormalities in 
mitochondria and decreased mitochondrial DNA content have 
been found in the subcutaneous fat of HIV patients receiving 
antiretroviral therapy, and have been directly linked to NRTI 
use, particularly with stavudine and zidovudine.63,64
PI use is thought to interfere with adipocyte matura-
tion through inhibition of adipocyte transcription factors 
sterol regulatory element binding protein-1 (SREBP-1) 
and the peroxisome proliferators-activated receptor gamma 
(  PPAR-γ).65–67 This inhibition is thought to drive the increased 
lipolysis and peripheral fat loss, with subsequent increased 
triglyceride esterification and central fat accumulation.
However, recent evidence has also shown a role of NRTI 
in inhibition of adipocyte maturation and differentiation. 
Indeed, NRTIs do independently reduce PPAR-γ expression, 
and continuous use of NRTIs appears to be the reason why 
rosiglitazone, a PPAR-γ-agonist, failed to show a benefit on 
HIV lipodystrophy.51,68
Finally, efavirenz (a non-nucleoside reverse transcriptase 
inhibitor) exerts a time-dependent decrease in expression of 
lipogenic transcription factor SREBP-1c, thus decreasing 
intracellular stores of TG.69
The hypothalamic pituitary axis 
in HIV-infected patients with 
lipodystrophy
GH is an important anabolic and lipolytic hormone produced 
by the somatotropic cells of the anterior pituitary gland. It 
is produced in a pulsatile release and its metabolic effects – 
increased muscle and bone mass and decreased body fat – are 
mostly mediated by insulin-like growth factor 1 (IGF-1), 
which is produced in response to growth hormone at various 
tissue sites.70
GH production is regulated by two stimulatory 
  peptides – growth hormone releasing hormone (GHRH), 
which is produced in the hypothalamus, and ghrelin, 
which is produced in the gastrointestinal tract and the 
hypothalamus – and by the inhibitory peptide somatostatin. 
Its production is also modulated by inhibitory feedback 
exerted by IGF-1 levels.
Mean GH levels, basal GH concentrations, and GH pulse 
amplitude are reduced in HIV-infected men with body-fat 
changes receiving ART, compared with men without body-
fat changes and healthy control subjects.27 Nearly half (48%) 
of the lipodystrophic patients did not achieve an adequate 
GH response to GHRH (using a peak GH stimulatory cut-
off of 5 µg/mL to GHRH). In another study of HIV-infected 
antiretroviral-experienced men with body-fat changes, 
approximately 20% were found to have inadequate GH 
stimulation in response to GHRH-arginine and appeared to 
be functionally GH deficient.71
Manipulation of the hypothalamic-
pituitary axis in the management  
of HIV-associated lipodystrophy:  
GH and GHRH
Growth hormone in the management  
of HIV-associated lipodystrophy
Increasing endogenous GH may reduce TGs and overall 
cholesterol levels through inhibition of de novo lipogenesis 
and increase in fat oxidation because recombinant human 
growth hormone (r-hGH) has been shown to reduce VAT 
and improve lipid levels in HIV-negative patients with GH 
deficiency.72 Indeed, early studies on r-hGH, given at doses 
ranging from 3 to 6 mg daily for 12 to 24 weeks, reduced 
abdominal fat and improved the lipid profile in HIV-infected 
patients with abnormal fat accumulation.73,74
A double-blind, placebo-controlled trial of 245 patients 
was designed to further evaluate the efficacy and safety of 
two dosing schemes of r-hGH therapy (4 mg every day vs 
4 mg every other day) for a period of 12 weeks, as a treatment 
of abdominal fat among HIV-infected patients (waist-to-hip 
ratio, WHR) . 0.95 and waist circumference . 88.2 cm in 
men or WHR . 0.90 and waist circumference . 75.3 cm in 
women). The investigators also explored the efficacy of the 
4 mg every other day dose as maintenance therapy following 
12-week administration of 4 mg every day.75
Compared with placebo, VAT decreased significantly 
from baseline to week 12 in the daily 4 mg dosing (−8.6%, 
P , 0.001) but not in alternate day dosing (−4.2%, P = 0.052). 
Trunk-to-limb fat ratio decreased significantly in both treat-
ment groups (P , 0.001) compared with placebo. There were HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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also modest but significant decreases in total cholesterol 
and nonhigh-density lipoprotein (non-HDL) cholesterol 
(−4.5% and −7.5%, respectively, in daily dosing; and −4.3% 
and −6.2% in alternate day dosing).
Another randomized, placebo-controlled trial of 325 sub-
jects randomized patients to 12-week administration of r-hGH 
4 mg daily vs placebo; with a 24-week maintenance phase 
(comparing r-hGH 2 mg on alternate days vs placebo).76
At week 12, induction therapy resulted in decreased 
VAT (23.6 vs 0.5 cm2; P , 0.001), limb fat (20.4 vs 0.2 kg; 
P , 0.001), and non-HDLs (213.0 vs 22.8 mg/dL; P = 0.023) 
compared with PL. On r-hGH induction-maintenance 
(baseline to week 36), patients sustained losses in VAT and 
trunk fat but not losses of subcutaneous fat in the abdomen 
or limbs.
In conclusion, a 12-week administration of supra-
physiological doses of GH (2–4 mg/d) to HIV-infected 
patients with abdominal obesity indeed led to decreased 
visceral fat, but was also associated with significant 
GH-related adverse events, including peripheral edema, 
arthralgias, and increased blood glucose.75,76 The adverse 
effects of rhGH have been deemed to be due to the fact that 
direct administration of GH leads to sustained high levels, 
rather than the physiologic pulsating levels of the endogenous 
hormone.
A subsequent study showed that the administration of 
a low dose of GH (titrated to elevation of the insulin-like 
growth factor [IGF-1] to the upper quartile of physiologic 
levels) for 18 months resulted in significantly reduced 
visceral fat and truncal obesity, TGs, and diastolic blood 
pressure. It also led to increased 2-hour glucose levels on 
glucose tolerance testing. The overall safety profile was 
good, as adverse effects were not increased in the GH vs 
placebo groups.77 Importantly, the long-term (18 months) 
administration of r-hGH was not associated with significant 
changes in the carotid intima media thickness, suggesting the 
beneficial effects of GH on VAT and lipid levels would not 
necessarily translate to improved cardiovascular risk.
Growth hormone releasing hormone 
in the management of HIV-associated 
lipodystrophy; tesamorelin
The administration of GHRH is expected to generate a 
more physiologic pattern of GH secretion among HIV-
infected patients, and avoid the aforementioned side effects 
resulting from supra-physiologic levels of GH. In a ran-
domized placebo-controlled trial,31 HIV-infected men with 
increased abdominal girth (WHR $ 0.90) were administered 
GHRH (1 mg subcutaneously twice daily) or placebo for 
12 weeks. GHRH resulted in a significant increase in IGF-1 
(104 ng/mL vs 6 ng/mL, P = 0.004). It also increased lean 
body mass (+0.9 kg vs −0.3 kg, P = 0.04) and decreased VAT 
(−19.2 cm2 vs +2.3 cm2; P = 0.07), although the latter was 
not statistically significant.78
One important factor limiting the development of GHRH 
as a viable therapeutic option was its rapid degradation 
in vivo by the serum enzyme dipeptidylaminopeptidase 4 
(DPP4). Synthetic analogs of GHRH were then investigated 
to render it resistant to hydrolysis by DPP4 through addition 
of a hydrophobic chain. This research led to the development 
of tesamorelin. Tesamorelin (previously known as TH9507) 
consists of a synthetically produced 44 amino acid sequence 
of human GHRH with a hexenoyl moiety attached to the 
tyrosine residue at the amino terminus.79–81
In preclinical studies, tesamorelin was found to be 
resistant to deactivation by DPP4, and markedly increased 
plasma levels of GH and IGF-1 after once daily dosing.81 
Tesamorelin was then shown to significantly reduce trunk 
fat and visceral adipose tissue, but not extremity fat, and 
to improve the lipid profile in randomized, controlled 
trials.82,83
In a dose-ranging study, 61 patients with WHR $ 0.94 
and WC $ 95 cm (for men) and WHR $ 0.88 and 
WC $ 94 cm (for women) were randomized to receive 1 mg 
or 2 mg of tesamorelin vs placebo for 12 weeks. The 2 mg 
group experienced significantly greater improvements in 
IGF-1 and significantly greater declines in visceral fat, TG, 
and cholesterol to HDL ratio (see Table 1). There was no 
increase in glucose levels.82
Safety and efficacy of tesamorelinin 
HIV-associated lipodystrophy
Two randomized controlled trials were then conducted 
to evaluate the safety and efficacy of tesamorelin in HIV-
infected patients with abdominal obesity.84,85 Patients on 
a stable antiretroviral regimen for at least 8 weeks were 
included if they had a waist circumference $95 cm and a 
WHR $ 0.94 for men, and a waist circumference $94 cm 
and a WHR $ 0.88 for women. Patients were excluded if 
they were receiving estrogen, GH or related products, or had 
a diagnosis of pituitary disease.
Patients were randomly assigned in a ratio of 2:1 to 
receive either 2 mg of tesamorelin or matching placebo, 
administered by subcutaneous injection. The studies HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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  consisted of two phases: the main phase, a 26-week study 
period was designed to assess the primary efficacy end 
point, that is, reduction in VAT from baseline. It was fol-
lowed by a 26-week extension phase to evaluate long-term 
safety. In this phase, patients who received tesamorelin 
in the first phase were again randomized to receive either 
tesamorelin or placebo in a ratio of 3:1; and patients receiv-
ing placebo in the main phase were assigned to receive 
tesamorelin.
The primary end point was the percentage change from 
baseline in VAT, defined as the number of square centimeters 
of visceral adipose tissue and as assessed by CT scanning 
using an analysis of covariance (ANCOVA). Secondary end 
points included the ratio of subcutaneous to visceral adipose 
tissue (VAT:SAT), changes in patient-reported outcomes 
related to body image, TG, ratio of total cholesterol to HDL, 
and IGF-1 levels. The first study enrolled 412 patients (86% 
of whom were men).84 The second enrolled 404 patients 
(84% were men).
Both studies showed concordant findings in the 
primary endpoint: a statistically significant decline in 
VAT at week 26 in the tesamorelin group compared with 
placebo: −27.8 cm2 vs +5.1 cm2 (relative difference of −20.2%), 
P , 0.001; −21 cm2 vs −1 cm2 (relative difference of −10.3%), 
P , 0.001, respectively84,85 (Table 1). There were also 
concordant declines in VAT:SAT:relative differences 
of −19.8%, P , 0.001; and −10.5, P , 0.001 (see Table 1). 
It is however important to note the somewhat different 
magnitude of effect observed in both trials. A subgroup 
analysis by gender presented in an FDA briefing on the 
drug (NDA 22-505) reported that the percent change from 
baseline in VAT was similar for females across studies but 
different for males (with larger reductions in the first study). 
Nonetheless, tesamorelin improved patient and physician 
ratings of abdominal profile in both studies.
Looking at the metabolic parameters, both studies also 
showed a remarkably similar increase in the level of IGF-1 
(+109 mg/mL and +106 ng/mL in the treatment groups).84,85 
There was some discrepancy between the two studies on the 
effect of tesamorelin on lipid levels. While TG levels in 
the tesamorelin group declined in both studies, this decline 
was only statistically significant in the first study (net dif-
ference of −59 mg/dL relative to placebo; P , 0.001);84 
but not in the second (−26 mg/dL; P = 0.10).85 Similarly, 
the   tesamorelin-to-placebo difference in changes of total 
cholesterol/HDL ratio was statistically significant only in 
the first study (−0.52 mg/dL; P , 0.001);84 but not in the 
second (−0.20 mg/dL; P = 0.1).85
In a pooled analysis of the two randomized controlled 
trials, there was a net reduction of VAT of 15.4% over 
26 weeks relative to placebo. VAT decreased by 24 cm2 in 
patients receiving tesamorelin compared with an increase of 
2 cm2 in patients receiving placebo.86 This reduction in waist 
circumference is almost exclusively a result of a reduction 
in VAT, because tesamorelin did not have a significant 
effect on abdominal SAT. Also, all improvements in lipid 
parameters were statistically significant in the tesamorelin 
group compared with placebo: TG (−37 mg/dL vs +6 mg/dL; 
P , 0.001); Cholesterol to HDL ratio (−0.18 vs +0.18; 
P , 0.001).
During the continuation phase of the studies, the 
improvement in VAT was not sustained among patients 
who were re-randomized to placebo after 26 weeks of 
therapy with tesamorelin (T-P). However, those randomized 
to continue tesamorelin for an additional 26 weeks (T-T) 
experienced a sustained reduction in VAT. Mean changes 
in VAT from baseline were −32 cm2 for T-T patients 
and −6 cm2 for T-P patients in the first study.84 Those 
changes were −41 cm2 for T-P vs −0 cm2 in T-P in the second 
study.85 Improvements in lipid profiles were also maintained 
only among patients who remained on tesamorelin. No 
significant changes in glucose parameters or immunological 
function were observed.
The rapid reversal of the tesamorelin effects on body fat 
and lipid levels upon discontinuation of therapy is probably 
explained by the reversal of IGF-1 increases. Among patients 
maintained on tesamorelin for 52 weeks, the IGF-1 levels 
remained at the levels achieved at week 26, but they returned 
to baseline for patients switched to placebo at week 26.84,85
Tesamorelin was found to be safe in this long-term 
follow-up. There were no significant changes in glucose and 
insulin levels over 52 weeks. None of the serious adverse 
events were deemed to be related to the study drug.   However, 
an FDA briefing document on the drug (NDA 22-505) 
reported a statistically significant difference in the propor-
tion of patients who developed diabetes mellitus in the 
tesamorelin group. Compared with placebo, odds ratios 
(95% confidence intervals) for developing diabetes were 3.4 
(1.3–11.5) or 3.6 (1.5–12.0) depending on whether baseline 
diabetes cases were excluded or not.
Implications of clinical efficacy 
studies of tesamorelin
In summary, tesamorelin has been shown to reduce VAT 
significantly, but this effect is transient and is reversed upon 
discontinuation of the medication. The beneficial impact of HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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tesamorelin on triglyceride levels has not been consistently 
shown across studies.
Two main cautionary points should then be raised 
  concerning the use of tesamorelin in HIV-infected patients 
with abdominal obesity:
1.  The effect of tesamorelin on VAT is not sustained with 
discontinuation of therapy. Patients in the Phase III 
trials who were switched from tesamorelin to placebo 
after 26 weeks demonstrated a re-accumulation of 
VAT to near baseline levels. Chronic therapy therefore 
appears to be necessary to maintain the reductions 
in VAT, with potential exposure to long-term side 
effects of GH and IGF-1 stimulation. Despite the fact 
that GHRH administration is expected to preserve 
more physiologic GH secretory pulsatility and IGF-1 
feedback inhibition, results from the clinical trials 
presented above show that patients are not free from 
IGF-1 related adverse events: compared with placebo, 
tesamorelin recipients were more likely to have an 
IGF-1 level above the upper limit of normal and more 
likely to develop diabetes.
2.  Because waist circumference and VAT have been shown 
to be independent predictors of cardiovascular morbidity 
and mortality,19,87 the investigators have suggested that 
reduction in VAT by tesamorelin might also reduce 
cardiovascular risk. However, this has not yet been 
investigated. It is not known if VAT reduction with 
therapies that target the GH axis is associated with any 
improvements in clinical endpoints such as reduction 
in number or severity of cardiovascular events or 
cardiovascular death. Indeed, the statistically significant 
increase in the proportion of patients with treatment-
emergent diabetes in the tesamorelin group vs placebo 
could adversely impact their cardiovascular risk.
The use of tesamorelin in HIV-infected patients should 
therefore be the result of a careful risk-to-benefit ratio 
analysis. One needs to make a determination whether 
the improvements in VAT – associated with inconsistent 
improvement in lipid profiles and unknown cardiovascular 
benefit – are worth the potential risk of chronic stimulation 
of the GH axis. These risks are feared to include pituitary 
hyperplasia or benign pituitary adenoma in an era of increased 
concerns over non-AIDS malignancies.
Conclusion
HIV/AIDS requires lifelong therapy with   combinations 
of antiretroviral drugs to maximally suppress viral 
  replication. Chronic exposure to these drugs can result in 
differential effects on body fat. Changes in body habitus 
are disfiguring, stigmatizing, and can cause psychological 
distress and negatively affect the quality of life. Moreover, 
the physical changes can lead to imperfect adherence to 
antiretroviral regimens, which can impact the virologic, 
immunologic, and clinical benefits of therapy. Regional 
body-fat loss and/or the accumulation associated with 
antiretroviral therapy therefore remain a concern and 
challenge in the management of HIV disease. A variety 
of therapeutic approaches, including insulin sensitizers 
and lifestyle modifications have not led to significant and 
sustained improvements.
The findings of low levels of GH in HIV-infected 
patients with lipodystrophy led to the development 
of tesamorelin for the management of this syndrome. 
Tesamorelin (previously known as TH9507) consists 
of a synthetically produced 44 amino acid sequence of 
human GHRH modified to render it resistant to enzymatic 
degradation and increase its half-life. It has now been 
shown to significantly reduce visceral adipose tissue 
among HIV-infected patients with central fat accumulation. 
However, this effect is transient and reversed upon 
cessation of therapy, and the long-term risk-benefit analysis 
of its administration is still unclear.
Currently, there are no evidence-based practice guidelines 
for the management of HIV-associated body-fat changes. 
The use of tesamorelin should therefore be evaluated in the 
context of multi-prong strategies to prevent, delay, or reduce 
these disfiguring morphologic changes due to the effect 
on quality of life and the potential risk for cardiovascular 
disease.
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